Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis-Reference-Cited by-同舟云学术

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis

Published:2016-02-17 Issue:3 Volume:10 Page:478-487
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Gane Edward J.,Rouzier Régine,Hassanein Tarek,Stedman Catherine A.,Mazur Wlodzimierz,Kupcova Viera,Le Pogam Sophie,Eng Simon,Voulgari Athina,Morcos Peter N.,Brennan Barbara J.,Scalori Astrid,Thommes James

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

http://link.springer.com/content/pdf/10.1007/s12072-015-9699-9.pdf

Reference28 articles.

1. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–1206

2. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–2416

3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207–1217

4. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417–2428

5. Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis. J Hepatol 2013;58:479–487

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

;Drug Design, Development and Therapy;2020-07

2. Danoprevir: First Global Approval;Drugs;2018-08

3. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo;Acta Pharmacologica Sinica;2018-06-21